ASPAVELI®▼ (pegcetacoplan)
Annual Vaccination Reminder

Dear Dr,

This communication is to remind you that patients being treated with pegcetacoplan may be predisposed to serious infections caused by encapsulated bacteria, including *Neisseria meningitidis*, *Streptococcus pneumoniae*, and *Haemophilus influenzae*. To reduce the risk of infection, all patients must be vaccinated against these bacteria according to applicable local guidelines at least 2 weeks prior to receiving pegcetacoplan, unless the risk of delaying therapy outweighs the risk of developing an infection. If immediate therapy is indicated, the required vaccines should be administered as soon as possible, and the patient treated with appropriate antibiotics until 2 weeks after vaccination.

Patients with known history of vaccination

Before receiving treatment with pegcetacoplan, the patient's vaccination history should be reviewed to ensure that they have received vaccines against encapsulated bacteria including *Streptococcus pneumoniae*, *Neisseria meningitidis* types A, C, W, Y, and B, and *Haemophilus influenzae* type B within 2 years prior to starting pegcetacoplan or according to applicable local guidelines.

Patients without known history of vaccination

For patients without a known history of vaccination, the required vaccines should be administered at least 2 weeks prior to receiving the first dose of pegcetacoplan. If immediate therapy is indicated, the required vaccines should be administered as soon as possible, and the patient treated with appropriate antibiotics until 2 weeks after vaccination.

Revaccination of patients

Patients that continue to be treated with pegcetacoplan must be revaccinated as per local vaccination guidelines.

Please check whether your patients require revaccination, and ensure they receive their vaccines according to applicable local guidelines to protect them against serious infections caused by encapsulated bacteria.

Thank you,
Sobi

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Report adverse events or safety concerns to the Health Products Regulatory Authority (HPRA) at www.hpra.ie. Adverse events can also be reported to Swedish Orphan Biovitrum Ltd at medical.info.uk@sobi.com or by calling +44 (0) 800 111 4754.

This letter is being sent by TCP Homecare on behalf of Swedish Orphan Biovitrum Ltd.

Swedish Orphan Biovitrum Ltd,
Suite 2, Riverside 3, Granta Park,
Great Abington,
Cambridgeshire,
CB21 6AD
www.sobi.com/uk/en

NP-40429 March 2025
Date of HPRA approval: March 2025 v1